The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound. The study is seeking participants who: Have completed treatment with nirmatrelvir/ritonavir Have a rebound in COVID-19 symptoms Are SARS-CoV-2 (COVID-19) positive All study medications will be taken 2 times a day by mouth for 5 days. The first dose of study medication is taken at the study clinic and the rest at home. We will examine the experiences of people receiving the study medicines to those who do not. This will help us determine if the study medicines are safe and effective. People taking part will be in this study for about 24 weeks. Enrolled participants will need to visit the study clinic at least 8 times during the study.
1 Primary · 4 Secondary · Reporting Duration: Day 1 through Day 28
411 Total Participants · 1 Treatment Group
Primary Treatment: nirmatrelvir plus ritonavir for 5 days · Has Placebo Group · Phase 2
Age Any Age · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: